Covington advised Eisai in the transaction. Eisai Co., Ltd. signed its agreement to transfer all future economic rights for elacestrant (generic name), approved for the treatment for...
DRI Healthcare Trust’s $85 Million of Royalty Interest in Breast Cancer Treatment
Verastem’s $85 Million Public Offering
Ropes & Gray advised Verastem, while Covington advised the underwriters in the offering. Verastem, Inc. announced its $85 million public offering of common stock and pre-funded warrants....
Roivant Sciences’ $150 Million Equity Offering
Davis Polk advised Roivant Sciences Ltd. in the deal, while Covington represented the underwriter, Cantor Fitzgerald. Roivant Sciences Ltd. announced its debut SEC-registered offering of 30,000,000...
Marinus Pharmaceuticals’ $60 Million Public Offering
Covington represented the underwriters on the deal. Marinus Pharmaceuticals, Inc. (Nasdaq: MRNS), a pharmaceutical company dedicated to the development of innovative therapeutics to treat seizure disorders,...